Home › Compound Library › Dapagliflozin (Farxiga)

Dapagliflozin (Farxiga)

SGLT2 Inhibitorprescriptionoral · predicted

SGLT2 inhibitor with similar mechanisms to empagliflozin, blocks renal glucose reabsorption, producing glycosuria, mild osmotic diuresis, and natriuresis. DAPA-HF and DAPA-CKD trials expanded indications beyond diabetes to heart failure (HFrEF) and chronic kidney disease regardless of diabetic status. Reduces HbA1c ~0.5-0.7%, weight ~2-3 kg, and SBP ~4 mmHg. 78% oral bioavailability.

Projected serum levels — 10 mg, once daily

Dapagliflozin (Farxiga)
Dapagliflozin (Farxiga) modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Dapagliflozin (Farxiga) modeled serum levels with a loading dose of 14.7 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 14.7 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 10.3 mg, trough ≈ 3.8 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
SGLT2 Inhibitor
Route modeled
Oral
Model confidence
predicted
Half-life
13 h
Common dose
10 mg
Suggested maximum
10 mg/day
Reference dose range
5–10 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.16 mg/L at 2 h

Documented interactions

  • danger
    CBD (Cannabidiol) + Dapagliflozin (Farxiga) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of UGT1A9 predicted to change Dapagliflozin (Farxiga) AUC by ~2.62x

  • moderate
    Carbamazepine (Tegretol) + Dapagliflozin (Farxiga) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Dapagliflozin (Farxiga) AUC by ~0.68x

  • moderate
    Efavirenz (Sustiva) + Dapagliflozin (Farxiga) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Dapagliflozin (Farxiga) AUC by ~0.55x

  • moderate
    Rifampin + Dapagliflozin (Farxiga) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Dapagliflozin (Farxiga) AUC by ~0.55x

  • moderate
    St. John's Wort (Hypericum perforatum) + Dapagliflozin (Farxiga) CYP induction

    St. John's Wort (Hypericum perforatum) inducer of CYP3A4 predicted to change Dapagliflozin (Farxiga) AUC by ~0.74x

  • watch
    Betamethasone + Dapagliflozin (Farxiga) CYP induction

    Betamethasone inducer of CYP3A4 predicted to change Dapagliflozin (Farxiga) AUC by ~0.89x

Serum checks 19 modeled interaction pairings for dapagliflozin (farxiga) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF) McMurray JJV et al. · New England Journal of Medicine, 2019 DOI

    Landmark RCT (4744 patients) demonstrating dapagliflozin reduced CV death or worsening HF by 26% in HFrEF regardless of diabetes status, establishing SGLT2 inhibitors as foundational HF therapy.

  2. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD) Heerspink HJL et al. · New England Journal of Medicine, 2020 DOI

    RCT stopped early for efficacy: dapagliflozin reduced kidney failure, sustained GFR decline, or death by 39% in CKD patients regardless of diabetes, transforming nephrology treatment guidelines.

2 published studies referenced in the app, each with a plain-language summary.